---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076575"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-16T00:00:53.640854+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q4 revenue $148.5M, net loss $31.3M; Regeneron deal >$1B

## Summary
- Q4 revenue $148.5M (down 19% YoY); net loss $31.3M ($0.04/share) vs $14.0M income in Q4 2024.
- Regeneron collaboration for multispecific antibodies: upfront + milestones >$200M per program, total >$1B.
- Pharmaceuticals revenue $43.7M (+17% YoY); NGENLA profit share $12.5M, Rayaldee $8.8M.
- Diagnostics revenue $71.1M (down 31% YoY) on asset sale; operating loss improved to $18.3M from $21.7M.
- FY 2026 guidance: total revenue $530-560M; total costs $725-750M; R&D $125-135M.

## SEC filing metadata
- accession: 0001193125-26-076575
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000119312526076575/0001193125-26-076575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000119312526076575/opk-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076575
- JSON: https://secwatch.observer/filing/0001193125-26-076575.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.